Multiple Scientific Posters Supporting the Efficacy, Safety and Tolerability of Once-daily Latuda® (lurasidone) are Presented at the 27th ECNP Congress

Takeda and Sunovion have presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions at the 27th European College of Neuropsychopharmacology (ECNP).

New data presented support Latuda's short and long-term efficacy, as well as preventing relapse.

This new data also supports Latuda as a tolerable option for patients switching medication from risperidone, having a low propensity for weight gain with minimal effects on cardiovascular and metabolic parameters.

Download to find out more.

More About This Company